Showing 1261-1270 of 10904 results for "".
- Data for PV-10 in Melanoma to be Presented at European Cancer Congresshttps://practicaldermatology.com/news/20130913-data_for_pv-10_in_melanoma_to_be_presented_at_european_cancer_congress/2459461/Analysis of data from Provectus Pharmaceuticals, Inc.'s completed Phase 2 study of intralesional PV-10 in metastatic melanoma will be presented at the upcoming European Cancer Congress (ECCO 17- ESMO-38 - ESTRO 32), taking place September 27 through
- Colorescience Expands Executive Teamhttps://practicaldermatology.com/news/20130531-colorescience_expands_executive_team/2459526/Colorescience appointed former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al
- MBA Aesthetics Course Finalizes Facultyhttps://practicaldermatology.com/news/20121017-mba_aesthetics_course_finalizes_faculty/2459703/“Mastering the Business of Aesthetics,” a one-day course taking place on October 27, will offer attendees insight on various clinical and financial elements of aesthetics practice. The faculty includes Paul S. Nassif, MD, FACS, Melanie Palm, MD, MBA, Nissan Pilest, MD, Robert James Troell, MD, FASC,
- Veil Cosmetics Introduced to Markethttps://practicaldermatology.com/news/20120727-veil_cosmetics_introduced_to_market/2459761/The concept of makeup artist Sébastien Tardif, Veil Cosmetics was inspired by Tardif's foundation in both art and fashion, which inspired the palette of bright-based colors that lift and illuminate the skin. Tardif cultivated his skincare sensibilities during his tenure in Asia, which led him
- La Roche-Posay Awards Two Researchershttps://practicaldermatology.com/news/20120514-la_roche-posay_awards_two_researchers/2459803/At its seventh annual North American Foundation Research Awards, La Roche-Posay honored winners Sarina B. Elmariah, MD, PhD and Marie S. Tuttle, MD. Both researchers received a $10,000 grant to continue dermatological research and were honored at t
- Rosacea Severity Linked to Metabolic Syndrome in New Cohort Studyhttps://practicaldermatology.com/news/rosacea-severity-linked-to-metabolic-syndrome-in-new-cohort-study/2488901/New research shows associations between rosacea severity, systemic inflammation, and metabolic syndrome. Published in Clinical, Cosmetic and Investigational Dermatology, the study included 298 patients with rosacea treated at a tertiary dermatology clinic in China between 2021 and
- International Consensus Clarifies Melasma Treatment Safety in Vitiligohttps://practicaldermatology.com/news/international-consensus-clarifies-melasma-treatment-safety-in-vitiligo/2488900/An international expert consensus sought to outline treatment strategies for patients with coexisting vitiligo and melasma, emphasizing disease activity, individualized treatment sequencing, and caution with depigmenting therapies. Researchers conducted a scoping literature review through
- PET/CT Shows High Specificity in Pediatric Melanoma Imaginghttps://practicaldermatology.com/news/pediatric-melanoma-imaging-petct-shows-high-specificity/2488829/A single-center retrospective study published in Children found that 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) demonstrated 90.3% diagnostic accuracy for detecting clinically active disease in children and adolescents with malignant melanoma.
- VALOR Data Show Sustained Skin Improvement With Brepocitinibhttps://practicaldermatology.com/news/valor-data-show-sustained-skin-improvement-with-brepocitinib/2488826/Once-daily oral brepocitinib 30 mg demonstrated rapid and sustained improvements in cutaneous disease activity, pruritus, and skin-related quality of life among adults with dermatomyositis, according to a prespecified secondary analysis of the phase 3 VALOR trial published in JAMA Dermatology